Sarepta Therapeutics, Inc.
NASDAQ: SRPT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Douglas S. Ingram
- Employees
- 1,372
- Headquarters
- Cambridge, United States
- IPO year
- 1997
- Market cap
- $1.8B
- Website
- https://www.sarepta.com
Loading SRPT…
Loading profile data…Frequently asked questions about SRPT
What does Sarepta Therapeutics, Inc. (SRPT) do?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy...
Where does SRPT trade?
Sarepta Therapeutics, Inc. (SRPT) trades on the NASDAQ Global Select.
What sector is SRPT in?
Sarepta Therapeutics, Inc. (SRPT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sarepta Therapeutics, Inc.?
Douglas S. Ingram is the chief executive officer of Sarepta Therapeutics, Inc. (SRPT).
Where is Sarepta Therapeutics, Inc. headquartered?
Sarepta Therapeutics, Inc. is headquartered in United States.
Does SRPT pay a dividend?
Sarepta Therapeutics, Inc. (SRPT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SRPT go public?
Sarepta Therapeutics, Inc. (SRPT) completed its initial public offering in 1997.